REQUEST A DEMO
Total
USD $0.00
Search more companies

Ucb S.R.O. (Czech Republic)

Main Activities: Research and Development in the Social Sciences and Humanities | Marketing Research and Public Opinion Polling
Secondary Activities: Other Chemical and Allied Products Merchant Wholesalers | Other Miscellaneous Nondurable Goods Merchant Wholesalers | Pharmacies and Drug Stores | All Other Business Support Services
Full name: Ucb S.R.O. Profile Updated: October 28, 2025
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English Download a sample report

UCB s.r.o., operating on the Czech market since 1993. Global biopharmaceutical company focused on the treatment and the development of therapies for serious diseases, operating in over 40 countries around the world. leader in the treatment of allergy and epilepsy and in research on antibodies, supported by a separate department of chemistry and more than 30 significant partners.

Headquarters
Jankovcova 1518/2
Prague; The City of Prague; Postal Code: 17000

Contact Details: Purchase the Ucb S.R.O. report to view the information.

Basic Information
Total Employees:
Purchase the Ucb S.R.O. report to view the information.
Registered Capital:
Purchase the Ucb S.R.O. report to view the information.
Financial Auditors:
Purchase the Ucb S.R.O. report to view the information.
Incorporation Date:
January 29, 1993
Key Executives
Purchase this report to view the information.
Legal Representative
Ownership Details
Purchase this report to view the information.
Company Performance
Financial values in the chart are available after Ucb S.R.O. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency CZK. Absolute financial data is included in the purchased report.
Net sales revenue
15.08%
Total operating revenue
15.09%
Operating profit (EBIT)
15.76%
EBITDA
15.52%
Net Profit (Loss) for the Period
172.71%
Total assets
-10.18%
Total equity
21.52%
Operating Profit Margin (ROS)
0.02%
Net Profit Margin
0.96%
Return on Equity (ROE)
9.82%
Quick Ratio
-0.1%
Cash Ratio
0.01%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?